Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Collectin-11 promotes cancer cell proliferation and tumor growth
Jia-Xing Wang, Bo Cao, Ning Ma, Kun-Yi Wu, Wan-Bing Chen, Weiju Wu, Xia Dong, Cheng-Fei Liu, Ya-Feng Gao, Teng-Yue Diao, Xiao-Yun Min, Qing Yong, Zong-Fang Li, Wuding Zhou, Ke Li
Jia-Xing Wang, Bo Cao, Ning Ma, Kun-Yi Wu, Wan-Bing Chen, Weiju Wu, Xia Dong, Cheng-Fei Liu, Ya-Feng Gao, Teng-Yue Diao, Xiao-Yun Min, Qing Yong, Zong-Fang Li, Wuding Zhou, Ke Li
View: Text | PDF
Research Article Immunology Oncology

Collectin-11 promotes cancer cell proliferation and tumor growth

  • Text
  • PDF
Abstract

Collectin-11 (CL-11) is a recently described soluble C-type lectin that has distinct roles in embryonic development, host defence, autoimmunity, and fibrosis. Here we report that CL-11 also plays an important role in cancer cell proliferation and tumor growth. Melanoma growth was found to be suppressed in Colec11–/– mice in a s.c. B16 melanoma model. Cellular and molecular analyses revealed that CL-11 is essential for melanoma cell proliferation, angiogenesis, establishment of more immunosuppressive tumor microenvironment, and the reprogramming of macrophages to M2 phenotype within melanomas. In vitro analysis revealed that CL-11 can activate tyrosine kinase receptors (EGFR, HER3) and ERK, JNK, and AKT signaling pathways and has a direct stimulatory effect on murine melanoma cell proliferation. Furthermore, blockade of CL-11 (treatment with L-fucose) inhibited melanoma growth in mice. Analysis of open data sets revealed that COLEC11 gene expression is upregulated in human melanomas and that high COLEC11 expression has a trend toward poor survival. CL-11 also had direct stimulatory effects on human tumor cell proliferation in melanoma and several other types of cancer cells in vitro. Overall, our findings provide the first evidence to our knowledge that CL-11 is a key tumor growth–promoting protein and a promising therapeutic target in tumor growth.

Authors

Jia-Xing Wang, Bo Cao, Ning Ma, Kun-Yi Wu, Wan-Bing Chen, Weiju Wu, Xia Dong, Cheng-Fei Liu, Ya-Feng Gao, Teng-Yue Diao, Xiao-Yun Min, Qing Yong, Zong-Fang Li, Wuding Zhou, Ke Li

×

Figure 4

TAMs from Colec11–/– mice exhibit less immunosuppressive features.

Options: View larger image (or click on image) Download as PowerPoint
TAMs from Colec11–/– mice exhibit less immunosuppressive features.
Tumor...
Tumors excised from Colec11+/+ (WT) or Colec11–/– (KO) mice (d14) were used for analyzing TAMs phenotypes by RNA-Seq. (A) Heatmaps of RNA-Seq data showing genes with significant differential expression (with fold change ≥ 1.5) between TAMs (CD45+F4/80+) from WT mice (TAM-WT) and KO mice (TAM-KO). Left panel: procancer pathway genes. Middle panel: chemokine genes encoding chemokines responsible for immune cell (myeloid cell, T cell, and NK cell) recruitment. Right panel: M1/M2-related genes. (B) FPKM gene expression levels corresponding to the 2 groups of TAMs in A. Data were analyzed by 2-way ANOVA with multiple-comparison test (n = 4 mice/group). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts